FDA OKs new Johnson & Johnson schizophrenia drug

12/21/2006 | USA Today

The FDA approved Johnson & Johnson's schizophrenia drug Invega, or paliperidone, which is derived from the drug risperidone, sold under the brand name Risperdal. Invega will be sold in extended-release tablet form. The price was not released.

View Full Article in:

USA Today

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX